

# 해외 바이오의약품 임상 현황 ('24년 4월 2주)

한국바이오의약품협회, 2024.04.16.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.  
- 출처: ClinicalTrials.gov  
- 모니터링 기간: 2024.04.08.~2024.04.14.  
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 8건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06064279</a>	Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC	Drug: Poly ICLC Drug: IVIG	VA Office of Research and Development Oncovir, Inc.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06064279</a>
<a href="#">NCT06311760</a>	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants	Drug: AZD0292 Drug: Placebo	AstraZeneca	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06311760</a>
<a href="#">NCT06138132</a>	A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis	Biological: KYV-101 anti-CD19 CAR-T cell therapy Drug: Standard lymphodepletion regimen	Stanford University Kyverna Therapeutics	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06138132</a>
<a href="#">NCT05805371</a>	PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer	Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Computed Tomography Radiation: External Beam Radiation Therapy Procedure: Leukapheresis Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT05805371</a>
<a href="#">NCT06338995</a>	A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Drug: LY3650150 Drug: Placebo Drug: Standard therapy for INCS	Eli Lilly and Company	Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06338995</a>
<a href="#">NCT06332339</a>	Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.	Biological: 16055 NFL delta Gly4 trimer Biological: Trimer 4571 Biological: Ad4-Env145NFL, 5 x 108 viral particles (vp)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06332339</a>
<a href="#">NCT06096779</a>	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis	Drug: Atezolizumab Drug: Bevacizumab	Genentech, Inc.	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06096779</a>
<a href="#">NCT06339008</a>	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	Drug: LY3650150 Drug: Placebo Drug: Standard therapy for INCS	Eli Lilly and Company	Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06339008</a>

○ 프랑스 1건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05300035</a>	Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control	Drug: Recombinant human monoclonal antibody (bNAbs) Drug: Placebo	ANRS, Emerging Infectious Diseases Rockefeller University Institut Pasteur	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT05300035</a>

해외 바이오의약품 임상 현황 ('24년 4월 2주)

한국바이오의약품협회, 2024.04.16.

○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06304961</a>	A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers	Biological: Tozorakimab	AstraZeneca	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06304961</a>
<a href="#">NCT05791409</a>	Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL	Drug: Epcoritamab Drug: Venetoclax	Stichting Hemato-Oncologie voor Volwassenen Nederland Nordic CLL Study Group German CLL Study Group	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05791409</a>

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06365008</a>	Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer	Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06365008</a>
<a href="#">NCT06350006</a>	SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor	Drug: SHR-A1904; Adbelimumab Drug: SHR-A1912; CAPOX; Adbelimumab	Shanghai Hengrui Pharmaceutical Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06350006</a>
<a href="#">NCT06205862</a>	Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)	Procedure: fecal microbiota transplantation	Shenzhen Hospital of Southern Medical University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06205862</a>